Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
News|Articles|February 17, 2015
FDA Updates Approved REMS
Author(s)Pharmaceutical Technology Editors
FDA gives an update on currently approved Risk Evaluation and Mitigation Strategies.
Advertisement
FDA has updated its approved Risk Evaluation and Mitigation Strategies (REMS). FDA requires REMS from manufacturers to ensure that the potential risks posed by drug products are outweighed by the benefits to patient health.
Products affected by the updates to the approved REMS include:
- Xeljianz (tofacitinib) tablets
- Buprenorphine Transmucosal Products for Opioid Dependence (BTOD)
- Extended-Release and Long-Acting Opioid Analgesics REMS
- Mycophenolate REMS
- Rosiglitazone REMS
- Transmucosal Immediate-Release Fentanyl (TIRF) Products
More information can be found at
Advertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Advertisement
Advertisement